Literature DB >> 833730

Application of salivary concentration data to pharmacokinetic studies with antipyrine.

P J Meffin, R L Williams, T F Blaschke, M Rowland.   

Abstract

The concentrations of antipyrine in plasma and saliva were equivalent in normal volunteers and in patients with acute viral hepatitis following oral doses of antipyrine. Estimates of clearance, volume of distribution, and half-life made from either plasma or saliva samples were not statistically different in these subjects. Differences in the disposition kinetics of anticted using either plasma or saliva samples.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 833730     DOI: 10.1002/jps.2600660140

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  8 in total

1.  Simplified determination of antipyrine clearance by liquid chromatography of a microsample of saliva or plasma.

Authors:  A el-Yazigi; D A Raines; H Ali; J Sieck; P Ernst; M Dossing
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

2.  Ethical considerations in the conduct of clinical pharmacokinetic studies.

Authors:  C K Svensson
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Salivary salicylate secretion and flow rate.

Authors:  M S Roberts; R H Rumble; P M Brooks
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

4.  Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

Review 5.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

6.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

7.  2-[(2-Carboxyphenyl)disulfanyl]benzoate (1,5-dimethyl-3-oxo-2-phenyl-2,3-di-hydro-1H-pyrazol-4-yl)ammonium.

Authors:  Jian-Zhong Huo
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-10-10

8.  1,5-Dimethyl-4-(1-methyl-3-oxo-3-phenylprop-1-enyl-amino)-2-phenyl-1H-pyrazol-3(2H)-one.

Authors:  Hualing Zhu; Zhan Wang; Junjie Ren; Miao Zhang; Wei Xu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2011-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.